[go: up one dir, main page]

AR055273A1 - Pi3-quinasas, sus usos y composiciones farmaceuticas que los contienen - Google Patents

Pi3-quinasas, sus usos y composiciones farmaceuticas que los contienen

Info

Publication number
AR055273A1
AR055273A1 ARP050104225A ARP050104225A AR055273A1 AR 055273 A1 AR055273 A1 AR 055273A1 AR P050104225 A ARP050104225 A AR P050104225A AR P050104225 A ARP050104225 A AR P050104225A AR 055273 A1 AR055273 A1 AR 055273A1
Authority
AR
Argentina
Prior art keywords
alkyl
het
alkenyl
aryl
nitrogen
Prior art date
Application number
ARP050104225A
Other languages
English (en)
Inventor
Steffen Breitfelder
Udo Maier
Trixi Brandl
Christoph Hoenke
Matthias Grauert
Alexander Pautsch
Matthias Hoffmann
Frank Kalkbrenner
Anne Joergensen
Gerhard Schaenzle
Stefan Petters
Eckhart Bauer
Frank Buettner
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102004048877A external-priority patent/DE102004048877A1/de
Priority claimed from DE102005005813A external-priority patent/DE102005005813A1/de
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR055273A1 publication Critical patent/AR055273A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/84—Naphthothiazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Debido a su accion farmacéutica como moduladores de la PI3-quinasa pueden utilizarse en el área terapéutica para el tratamiento de enfermedades inflamatorias o alérgicas. A modo de ejemplo, se mencionan enfermedades inflamatorias o alérgicas de las vías respiratorias, enfermedades inflamatorias del tracto gastro-intestinal, artritis reumatoidea, patologías dérmicas inflamatorias y alérgicas, patologías oftálmicas inflamatorias, patologías de la mucosa nasal, estados patologicas inflamatorios o alérgicos, en los cuales inciden reacciones autoinmunes o inflamaciones renales. Reivindicacion 1: Compuestos de formula (1), con la condicion, que la línea circular identificada con A significa un sistema aromático; donde Y significa carbono, átomo de nitrogeno, azufre; de preferencial carbono, nitrogeno; Z significa carbono, nitrogeno, azufre; de preferencia carbono, nitrogeno; j 1, 2 o 3; k 0 o 1; Ra es H, COR8, NR9R10, NO2, OR8, SR11, SOR11, SO2R11, NHCO-alquiloC1-6-NH2, o un radical seleccionado del grupo que incluye alquilo C1-6, alquenilo C2-6, cicloalquilo C3-8, cicloalquenilo C3-8, haloalquilo C1-6, arilo, aralquilo C7-11, espiro, Het, heteroarilo y CH2-O-arilo, que en su caso puede estar sustituido; R8 significa alquilo C1- 6, cicloalquilo C3-6, NH2, hetarilo o arilo, en su caso sustituido con uno o varios halogenos o alquilo C1-4; R9 significa H, COOR12, CONR12 o alquilo C1-6, en su caso sustituido con uno o varios COOH, N(alquilo C1-6)2 o Het, en su caso sustituido con uno o varios alquilo C1-6; o R9 significa Het, en su caso sustituido con uno o varios alquilo C1-4; R10 significa H, alquilo C1-6, CO-alquiloC1-6 o alquinilo C2-6; R11 significa alquilo C1-6, en su caso sustituido con uno o varios N(alquilo C1- 4)2; Rb es R4, OR4, -CH2OR4, COR4, COOR4, CONR4R5, NR4R5, NR5COR4, NR5COOR4, NR5CONR4R5, NR5SOR4 o NR5SO2R4; R4, R5 significan H, alquilo C1-6, haloalquilo C1-6, alquileno C1-6-OH, alquenilo C2-6, aralquilo C7-11, alqueniloC2-4-arilo, alquiniloC2-4- arilo, alquiloC1-4-hetarilo, alqueniloC2-4-hetarilo, alquiniloC2-4-hetarilo, alquinilo C2-6, en su caso sustituido con Si(alquilo C1-4)3, o R4 significa un radical seleccionado del grupo que incluye arilo, Het, Hetarilo y en su caso alquilo C1-4; o R4 y R5 forman conjuntamente un anillo de cinco, seis o siete miembros que se compone de átomo de carbono y en su caso un heteroátomo seleccionado del grupo que se compone de oxígeno, nitrogeno y azufre; Rc significa NHR6 o un radical seleccionado del grupo que incluye la formula (2) donde: B significa un enlace, alquilo C1-6, alquenilo C2-6 o alquinilo C2-6; R6 es H o un radical seleccionado del grupo alquilo C1-4, alquenilo C2-4, alquinilo C2-4, cicloalquilo C3-6, cicloalquenilo C3-6, Het, arilo, hetarilo en su caso sustituido con uno o varios radicales R6,1; R6,1 es halogeno, CF3, OH, CN, OMe, SO2(alquilo C1-4); R7 significa H, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, cicloalquilo C3-6, NR7,1R7,2, OR7,2, SR7,2, hetarilo, Het, en su caso sustituido con alquilo C1-4 o CONH2; R7,1 significa H, alquilo C1-6, (CH2)2-4R7,1,1 o COO-butilo; R7,2 significa H, alquilo C1-6, en su caso sustituido con uno o varios OH; R7,1,1NR7,1,1,1R7,1,1,2, Het o 1-imidazolilo, 2-(N-etilpirrolidina); R7,1,1,1 es H o alquilo C1-6; R7,1,1,2 es H o alquilo C1-6; así como sales aceptables para uso farmacéuticos, diaesteromeros, enantiomeros, racematos, hidratos o solvatos de éstos, con la condicion, que Ra no puede ser H o Me, cuando significan Y = nitrogeno; Z = nitrogeno; j = 2; k = 0; Rb= H y Rc = NHCONH-Et.
ARP050104225A 2004-10-07 2005-10-07 Pi3-quinasas, sus usos y composiciones farmaceuticas que los contienen AR055273A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004048877A DE102004048877A1 (de) 2004-10-07 2004-10-07 PI3-Kinasen
DE102005005813A DE102005005813A1 (de) 2005-02-09 2005-02-09 PI3-Kinasen

Publications (1)

Publication Number Publication Date
AR055273A1 true AR055273A1 (es) 2007-08-15

Family

ID=35583390

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104225A AR055273A1 (es) 2004-10-07 2005-10-07 Pi3-quinasas, sus usos y composiciones farmaceuticas que los contienen

Country Status (14)

Country Link
US (4) US7691888B2 (es)
EP (2) EP1802636B1 (es)
JP (1) JP5122287B2 (es)
KR (1) KR20070064660A (es)
CN (1) CN101048418A (es)
AR (1) AR055273A1 (es)
AU (1) AU2005293607A1 (es)
BR (1) BRPI0516557A (es)
CA (1) CA2579279C (es)
IL (1) IL182398A0 (es)
MX (1) MX2007004051A (es)
RU (2) RU2007116861A (es)
TW (1) TW200628475A (es)
WO (1) WO2006040279A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050096332A1 (en) * 2003-10-30 2005-05-05 Boehringer Ingelheim International Gmbh Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
EP1802636B1 (de) * 2004-10-07 2013-03-27 Boehringer Ingelheim International Gmbh Pi3-kinasen inhibitoren
US7691868B2 (en) * 2006-04-06 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-quinazoline
US20070259855A1 (en) * 2006-04-06 2007-11-08 Udo Maier Thiazolyl-dihydro-indazole
US7517995B2 (en) * 2006-04-06 2009-04-14 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-cyclopentapyrazole
US20070238746A1 (en) * 2006-04-06 2007-10-11 Trixi Brandl Thiazolyl-dihydro-chinazoline
US20070238718A1 (en) * 2006-04-06 2007-10-11 Matthias Grauert Thiazolyl-dihydro-indazole
AU2007233728A1 (en) * 2006-04-06 2007-10-11 Boehringer Ingelheim International Gmbh Thiazolyl dihydro-indazoles
DE602006002385D1 (de) * 2006-06-26 2008-10-02 Helm Ag Verfahren zur Herstellung von Pramipexole
WO2008001883A1 (fr) * 2006-06-29 2008-01-03 Nissan Chemical Industries, Ltd. DÉRIVÉ D'ACIDE α-AMINÉ ET PRODUIT PHARMACEUTIQUE QUI LE COMPREND EN TANT QUE MATIÈRE ACTIVE
US8779154B2 (en) 2006-09-26 2014-07-15 Qinglin Che Fused ring compounds for inflammation and immune-related uses
GB0619611D0 (en) 2006-10-04 2006-11-15 Ark Therapeutics Ltd Compounds and their use
WO2009039140A1 (en) * 2007-09-17 2009-03-26 Smithkline Beecham Corporation Pyridopyrimidine derivatives as pi3 kinase inhibitors
JP2011509261A (ja) * 2008-01-07 2011-03-24 シンタ ファーマシューティカルズ コーポレーション 炎症および免疫関連用途向けの化合物
UY31700A (es) 2008-03-13 2009-11-10 Boehringer Ingelheim Int Tiazolil-dihidro-indazoles
WO2009120826A1 (en) * 2008-03-27 2009-10-01 Wyeth 2-aryl- and 2-heteroarylthiazolyl compounds, methods for their preparation and use thereof
ES2480994T3 (es) 2008-03-31 2014-07-29 Genentech, Inc. Compuestos de tipo benzopirano y benzoxepina inhibidores de PI3K y métodos de uso
KR20100122513A (ko) * 2008-07-17 2010-11-22 아사히 가세이 파마 가부시키가이샤 질소 함유 복소환 화합물
JPWO2010024258A1 (ja) * 2008-08-29 2012-01-26 塩野義製薬株式会社 Ｐｉ３ｋ阻害活性を有する縮環アゾール誘導体
WO2010043676A1 (en) * 2008-10-17 2010-04-22 Boehringer Ingelheim International Gmbh Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (pi3-kinases) inhibitor
GB0900404D0 (en) 2009-01-12 2009-02-11 Addex Pharmaceuticals Sa New compounds 4
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
EP2421872B1 (en) 2009-04-22 2015-06-10 Boehringer Ingelheim International GmbH Thia-triaza-as-indacenes as pi3-kinases inhibitors for the treatment of cancer
US8288379B2 (en) 2009-04-22 2012-10-16 Boehringer Ingelheim International Gmbh Thia-triaza-cyclopentazulenes
MX2012000178A (es) * 2009-07-02 2012-02-28 Novartis Ag 2-carboxamida-cicloamino-ureas utiles como inhibidores de pi3k.
SG10201404886PA (en) 2009-08-17 2014-10-30 Intellikine Llc Heterocyclic compounds and uses thereof
RU2600927C2 (ru) 2009-09-28 2016-10-27 Ф.Хоффманн-Ля Рош Аг Бензоксазепиновые ингибиторы pi3k и способы применения
AU2010299820A1 (en) 2009-09-28 2012-04-19 F. Hoffmann-La Roche Ag Benzoxepin PI3K inhibitor compounds and methods of use
EP2499146B1 (en) 2009-11-13 2016-09-21 Merck Serono S.A. Tricyclic pyrazol amine derivatives
US9096590B2 (en) 2010-05-24 2015-08-04 Intellikine Llc Substituted benzoxazoles as PI3 kinase inhibitors
GB201011831D0 (en) 2010-07-14 2010-09-01 Addex Pharmaceuticals Sa New compounds 5
EP2593277A4 (en) * 2010-07-14 2014-09-03 Addex Pharmaceuticals Sa Novel condensed pyrazoline derivatives and their use as allosmetic modulators of metabotropic glutamate receptors
TW201245176A (en) 2011-01-26 2012-11-16 Boehringer Ingelheim Int New 5-alkynyl-pyridines
US8466162B2 (en) 2011-01-26 2013-06-18 Boehringer Ingelheim International Gmbh 5-alkynyl-pyridines
EP2546249A1 (en) 2011-07-15 2013-01-16 Boehringer Ingelheim International Gmbh 5-Alkynyl-pyridines
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
WO2012148540A1 (en) 2011-02-23 2012-11-01 Intellikine, Llc Combination of kanase inhibitors and uses threof
CN103562210B (zh) 2011-03-21 2016-05-25 弗·哈夫曼-拉罗切有限公司 对pI3K 110δ具有选择性的苯并氧氮杂*化合物及使用方法
RU2014128386A (ru) * 2012-02-06 2016-03-27 ГлаксоСмитКлайн Интеллекчуал Проперти (N 2) Лимитед Ингибиторы PI3K для лечения кашля
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
MX2021007925A (es) 2018-12-31 2021-10-26 Biomea Fusion Llc Inhibidores irreversibles de la interaccion menina-mll.
TW202043205A (zh) 2018-12-31 2020-12-01 美商拜歐米富士恩有限公司 Menin-mll相互作用之抑制劑
WO2023018825A1 (en) 2021-08-11 2023-02-16 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
TW202313004A (zh) 2021-08-20 2023-04-01 美商拜歐米富士恩股份有限公司 Ｍｅｎｉｎ－ｍｌｌ相互作用之不可逆抑制劑的結晶形式
WO2024155719A1 (en) 2023-01-18 2024-07-25 Biomea Fusion, Inc. Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2- pyridinecarboxamide as a covalentinhibitor of menin-mll interaction

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2036026A (en) 1978-05-17 1980-06-25 Teijin Ltd Hexahydronaphthoimidazothiazoles and process for preparing same
JPS5533405A (en) 1978-08-29 1980-03-08 Teijin Ltd Hexahydronaphtho(1',2':4,5)imidazo(2,1-b)thiazole and its preparation
DE3572485D1 (en) * 1984-12-22 1989-09-28 Thomae Gmbh Dr K Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs
US5358949A (en) * 1986-03-05 1994-10-25 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives
US5182290A (en) * 1991-08-27 1993-01-26 Neurogen Corporation Certain oxazoloquinolinones; a new class of GABA brain receptor ligands
TW260664B (es) * 1993-02-15 1995-10-21 Otsuka Pharma Factory Inc
JP3670309B2 (ja) 1993-04-01 2005-07-13 第一製薬株式会社 二環性複素環化合物
NO941135L (no) 1993-04-01 1994-10-03 Daiichi Seiyaku Co Tiazolpyrimidin derivater
AU727654B2 (en) * 1997-06-13 2000-12-21 Yamanouchi Pharmaceutical Co., Ltd. Tricyclic pyrazole derivative
HUP0300359A2 (hu) * 2000-02-07 2003-06-28 Abbott Gmbh & Co. Kg. 2-Benzotiazolil-karbamid-származékok és protein kináz inhibitorként történő felhasználásuk és ezeket tartalmazó gyógyszerkészítmények
CN100355751C (zh) * 2000-03-29 2007-12-19 西克拉塞尔有限公司 2－取代的4－杂芳基－嘧啶、其组合物及其用途
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
KR100423899B1 (ko) * 2000-05-10 2004-03-24 주식회사 엘지생명과학 세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸
WO2003035618A2 (en) 2001-10-24 2003-05-01 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
TWI314928B (en) 2002-02-28 2009-09-21 Novartis A 5-phenylthiazole derivatives and use as pi3 kinase inhibitors
EP1349179A1 (en) * 2002-03-18 2003-10-01 ATOFINA Research Conductive polyolefins with good mechanical properties
BR0312650A (pt) 2002-07-10 2005-05-03 Applied Research Systems Derivados de benzeno fundido azolidinona-vinila
ATE411996T1 (de) 2002-09-30 2008-11-15 Bayer Healthcare Ag Kondensierte azolpyrimidinderivate
JP2006510661A (ja) 2002-12-06 2006-03-30 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Ｐｉ３ｋの阻害剤としてのベンズオキサジン−３−オン類及びその誘導体
CA2510851A1 (en) 2002-12-20 2004-07-08 Warner-Lambert Company Llc Benzoxazines and derivatives thereof as inhibitors of pi3ks
GB0315966D0 (en) * 2003-07-08 2003-08-13 Cyclacel Ltd Compounds
NO20041733L (no) * 2004-04-28 2005-10-31 Thin Film Electronics Asa Organisk elektronisk krets med funksjonelt mellomsjikt og fremgangsmate til dens fremstilling.
EP1802636B1 (de) * 2004-10-07 2013-03-27 Boehringer Ingelheim International Gmbh Pi3-kinasen inhibitoren
FR2887993B1 (fr) * 2005-07-01 2007-08-03 Commissariat Energie Atomique Dispositif de detection de rayonnements a electrodes empilees et methode de detection de rayonnements ionisants mettant en oeuvre un tel dispositif
WO2007113246A1 (de) * 2006-04-06 2007-10-11 Boehringer Ingelheim International Gmbh Thiazolyldihydroindazol-derivate als proteinkinase- inhibitoren
US20070259855A1 (en) * 2006-04-06 2007-11-08 Udo Maier Thiazolyl-dihydro-indazole

Also Published As

Publication number Publication date
WO2006040279A1 (de) 2006-04-20
IL182398A0 (en) 2007-07-24
JP5122287B2 (ja) 2013-01-16
US20060100254A1 (en) 2006-05-11
BRPI0516557A (pt) 2008-09-09
CN101048418A (zh) 2007-10-03
US20100113414A1 (en) 2010-05-06
RU2007116861A (ru) 2009-03-20
EP1802636B1 (de) 2013-03-27
CA2579279A1 (en) 2006-04-20
KR20070064660A (ko) 2007-06-21
CA2579279C (en) 2013-10-01
TW200628475A (en) 2006-08-16
US7691888B2 (en) 2010-04-06
JP2008515852A (ja) 2008-05-15
US20060106013A1 (en) 2006-05-18
RU2403258C2 (ru) 2010-11-10
US8207349B2 (en) 2012-06-26
EP1802636A1 (de) 2007-07-04
RU2007116858A (ru) 2008-12-27
US20090156554A1 (en) 2009-06-18
AU2005293607A1 (en) 2006-04-20
US8232286B2 (en) 2012-07-31
MX2007004051A (es) 2007-05-24
EP2343303A1 (de) 2011-07-13

Similar Documents

Publication Publication Date Title
AR055273A1 (es) Pi3-quinasas, sus usos y composiciones farmaceuticas que los contienen
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
AR059010A1 (es) 6-( aril polisustituido )-4- aminopicolinatos y su uso como herbicidas
AR015176A1 (es) Derivados pirazol y derivados de pirazol condensados que incluyen indazoles, su procedimiento de preparacion, preparado farmaceutico y su utilizacionpara la preparacion de medicamentos.
AR060265A1 (es) Tiazolil - dihidro -quinazolinas
AR074358A1 (es) Derivados de pirazina como inhibidores de la fosfodiesterasa 10
AR122049A2 (es) Derivados de pirimidiniloxi benceno como herbicidas
EA200600527A1 (ru) Активирующее ppar соединение и содержащая его фармацевтическая композиция
UY29882A1 (es) Antagonistas del receptor 3 de la histamina
AR029919A1 (es) Fenil sulfamoil carboxamidas sustituidas con uracilo
AR062695A1 (es) N-(1- ftalazin -1--il- piperidin -4-il) - amidas como moduladores del receptor ep2
AR061994A1 (es) Uso de derivados de imidazol activadores de ampk, su proceso de preparacion y composiciones farmaceuticas que los comprenden
AR075597A1 (es) Derivados de indol como antagonistas de receptores crth2, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del asma y otras enfermedades alergicas .
AR052886A1 (es) Procedimientos para preparar fenilpirazol ureas sustituidas y para la obtencion de sus intermediarios de sintesis
AR037682A1 (es) Derivados de acetileno que tienen actividad antagonista para receptores glutamato metabotropico humanos, composicion farmaceutica, una combinacion y el uso de dichos derivados para la fabricacion de composiciones farmaceuticas
AR091786A1 (es) Inhibidores de la produccion de leucotrienos
AR060268A1 (es) Tiazolil - dihidro - indazoles
AR058296A1 (es) Inhibidores de histona desacetilasa y composicion farmaceutica
AR072085A1 (es) Compuestos triciclicos, metodos para su preparacion, composicion farma-ceutica que los comprende y su uso en el tratamiento de enfermedades me-diadas por la actividad de las proteinas quinasas
AR060267A1 (es) Tiazolil- dihidro -ciclopentapirazoles
AR118826A1 (es) Inhibidores de cinasas raf
AR070187A1 (es) Derivados de dulfonamidas sustituidas
AR053092A1 (es) Compuestos derivados de acido fenoxiacetico y compuestos intermediarios de sintesis
AR053135A1 (es) Compuestos betamimeticos eficaces a largo plazo para el tratamiento de enfermedades respiratorias

Legal Events

Date Code Title Description
FB Suspension of granting procedure